Ocuphire Pharma Investor Day Presentation Deck

VEGA-1: Presbyopia Phase 2 Trial Design P Randomized, Double-Masked, Placebo-Controlled, Multi-Center One-Week Trial 80 ● ● ● VEGA-1 17 US sites 150 presbyopic patients 0.75% Nyxol arms Placebo Randomization Visit 1 (Day 1) Baseline Baseline Baseline Baseline Screening Evening Dosing (3-4 doses) Nyxol Nyxol Placebo Placebo Visit 2 (Day 5) LDP Drop No Treatment LDP Drop No Treatment Treatment Arms Nyxol + LDP Nyxol Alone LDP Alone Placebo Alone Eligibility Criteria Males or females ≥ 40 and ≤ 64 years of age BCDVA of 0.0 LogMAR(20/20 Snellen equivalent) or better in each eye under photopic conditions DCNVA of 0.4 LogMAR (20/50 Snellen equivalent) or worse in photopic conditions in each eye & binocularly Phase 2 Enrollment Completed Feb to May 2021 – 150 Subjects Reported Topline Results End of 2Q21 Endpoints Primary: % of subjects with ≥ 3 lines of improvement in distance- corrected near visual acuity comparing Nyxol + LDP vs placebo alone at 1 hour Secondary: • % of subjects with ≥ 2 and ≥ 3 lines gained at time points from 30 min to 6 hours in photopic lighting comparing Nyxol + LDP vs placebo, Nyxol alone, and LDP alone ● % of subjects with > 3 lines of near vision gain with less than 5 letters of distance loss Pupil diameter at time points Safety and tolerability Clinical trial NCT #04675151. DCNVA = distance-corrected near visual acuity. BCDVA = best corrected distance visual acuity; *3-4 evenings; VEGA-1 Study Design Ocuphire PHARMA

View entire presentation